Keywords: Crohn’s disease; dose escalation; inflammatory bowel disease; loss of response; optimization; ulcerative colitis; ustekinumab.
In this retrospective cohort study, we demonstrated that dose intensification of ustekinumab to every 4 or every 6 weeks was effective in both achieving and maintaining clinical remission for >40% of inflammatory bowel disease patients for up to 24 months.